Life sciences: Lab notes from Bristows | Three competition law risks to watch out for

What competition law risks should life sciences companies be watching out for? 

In this episode, Bristows competition lawyers Sophie Lawrance and Francion Brooks explore three key areas for in-house counsel to monitor: patent strategies, denigration and so-called “killer acquisitions”. They discuss recent enforcement trends and cases, the practical risks for innovative pharma companies, and the steps businesses should consider to stay on the right side of competition law.

All information was correct at the time of recording.